LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Quality Control Reference for Monitoring NGS-Based Tumor Profiling Assays

By LabMedica International staff writers
Posted on 20 Jul 2015
Print article
Image: The Seraseq Solid Tumor Mutation Mix kit (Photo courtesy of SeraCare).
Image: The Seraseq Solid Tumor Mutation Mix kit (Photo courtesy of SeraCare).
A newly released kit was designed to enable genomics researchers and drug developers to evaluate the performance of next generation sequencing (NGS)-based tumor profiling assays.

The SeraCare Life Sciences (Milford, MA, USA) Seraseq Solid Tumor Mutation Mix-I reference material is a mixture of biosynthetic target genes with specific engineered mutations in a wild-type background of well-characterized genomic DNA and is compatible with all major cancer hotspot oncology panels and NGS platforms on the market today. The reference matrix contains a mixture of mutations in key oncogenes and tumor suppressor genes and is intended as a quality control standard for translational and disease research testing.

This "for research use only" version includes 26 major cancer hotspot genes, all at 20% allelic frequency and quantified using digital PCR to ensure highest accuracy. The material is stable for two years under recommended storage conditions, and can undergo ten freeze-thaw cycles without any degradation of performance.

"SeraCare's extensive background and experience with the manufacture of quality reference and validation materials under cGMP ISO standards has enabled us to develop the Seraseq Solid Tumor Mutation Mix," said Dr. Russell Garlick, CSO at SeraCare. "This technology allows almost unlimited breadth of mutations and can be accurately "tuned" to specific allelic frequencies because we have incorporated digital PCR in the manufacturing. With this product, we can partner with in vitro diagnostics developers and clinical labs to offer a powerful performance tracking tool for their NGS tumor profiling assays."

Related Links:

SeraCare Life Sciences


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more